Membership Home Portfolio Stocks Bonds Funds ETFs CEFs Markets Tools Real Life Finance Discuss
Home>Topics>>Vical's Herpes Vaccine: New Lab Results Confirm Move To The Clinic

Vical's Herpes Vaccine: New Lab Results Confirm Move To The Clinic

Long Investing Ideas from Seeking Alpha

Mon, 4 Feb 2013

By Theodore Cohen: In August 2011 and February 2012 I pre sented detailed overviews of Vical Incorporated's ( VICL ) herpes simplex virus type 2 or HSV-2 vaccine . Of the two serotypes identified, HSV-1 and HSV-2, the former is more common in the United States, but the latter is considered more ...

Read the rest of this article on Long Investing Ideas from Seeking Alpha

Related Topics:

  1. Vical Incorporated
Content Partners
Site Directory Site Map Our Products
Corrections Help Advertising Opportunities Licensing Opportunities Glossary RSS Mobile Portfolio Affiliate Careers Company News
International Sites: Australia Canada China France Germany Hong Kong Italy The Netherlands Norway Spain U.K. Switzerland India Finland
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.

© Copyright 2013 Morningstar, Inc. All rights reserved. Please read our Terms of Useand Privacy Policy.Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.